GT Biopharma, Inc. (GTBP): Nasdaq/NYSE listing notice — GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share

GT Biopharma, Inc.

Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.
Has 180 calendar days, until August 21, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.
May qualify for a second 180-day period if it meets other listing standards and provides written notice.
Company intends to monitor bid price and consider available options to cure the deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 22, 2023, GT Biopharma, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.